A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs DEBIO 1562 (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Debiopharm; ImmunoGen
- 31 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Oct 2019.
- 31 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2019.
- 05 May 2016 Treatment arms changed from 1 to 2 arm, Time frame for primary endpoint (adverse events) changed from upto 100 months to 12 months.